{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T16:41:05Z","timestamp":1769359265558,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"DOI":"10.7759\/cureus.102134","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:46:28Z","timestamp":1769165188000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeting the IL-36 Pathway: Spesolimab as a Therapeutic for Acute Flares of Pustular Psoriasis"],"prefix":"10.7759","author":[{"given":"Esther","family":"Nwozo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devon","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.09.035","article-title":"Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis","volume":"149","author":"Baum P","year":"2022","unstructured":"Baum P, Visvanathan S, Garcet S, et al.. Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022, 149:1402-12. 10.1016\/j.jaci.2021.09.035","journal-title":"J Allergy Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0519-3","article-title":"\"Autoinflammatory psoriasis\"-genetics and biology of pustular psoriasis","volume":"18","author":"Uppala R","year":"2021","unstructured":"Uppala R, Tsoi LC, Harms PW, et al.. \"Autoinflammatory psoriasis\"-genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021, 18:307-17. 10.1038\/s41423-020-0519-3","journal-title":"Cell Mol Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00654-z","article-title":"Clinical course and characteristics of generalized pustular psoriasis","volume":"23","author":"Choon SE","year":"2022","unstructured":"Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022, 23:21-9. 10.1007\/s40257-021-00654-z","journal-title":"Am J Clin Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14949","article-title":"Generalized pustular psoriasis: a review and update on treatment","volume":"32","author":"Hoegler KM","year":"2018","unstructured":"Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018, 32:1645-51. 10.1111\/jdv.14949","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094529","article-title":"Psoriasis and gut microbiome-current state of art","volume":"22","author":"Polak K","year":"2021","unstructured":"Polak K, Bergler-Czop B, Szczepanek M, Wojciechowska K, Fr\u0105tczak A, Kiss N. Psoriasis and gut microbiome-current state of art. Int J Mol Sci. 2021, 22:10.3390\/ijms22094529","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133318","article-title":"The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","volume":"20","author":"Madonna S","year":"2019","unstructured":"Madonna S, Girolomoni G, Dinarello CA, Albanesi C. The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis. Int J Mol Sci. 2019, 20:10.3390\/ijms20133318","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2019.05.007","article-title":"State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis","volume":"46","author":"Gisondi P","year":"2019","unstructured":"Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol. 2019, 46:90-9. 10.1016\/j.coph.2019.05.007","journal-title":"Curr Opin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez H","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, et al.. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021, 385:2431-40. 10.1056\/NEJMoa2111563","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241252688","article-title":"Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis","volume":"59","author":"Pathak GN","year":"2025","unstructured":"Pathak GN, Wang E, Dhillon J, Parikh PN, Esseghir R, Rao BK, Feldman SR. Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis. Ann Pharmacother. 2025, 59:174-83. 10.1177\/10600280241252688","journal-title":"Ann Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64474","article-title":"Effective management of life-threatening generalized pustular psoriasis flare with spesolimab","volume":"16","author":"Zafiriou E","year":"2024","unstructured":"Zafiriou E, Karampinis E, Giannoulis G, Gravani A, Gampeta S, Zachou K. Effective management of life-threatening generalized pustular psoriasis flare with spesolimab. Cureus. 2024, 16:e64474. 10.7759\/cureus.64474","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad389","article-title":"Spesolimab treatment in a patient with generalized pustular psoriasis: a case report with 12-month follow-up and literature review","volume":"49","author":"Cardenas-de la Garza JA","year":"2024","unstructured":"Cardenas-de la Garza JA, Zazueta-L\u00f3pez RM, Garza-Elizondo AK, Flores-Gutierrez DP, Welsh E. Spesolimab treatment in a patient with generalized pustular psoriasis: a case report with 12-month follow-up and literature review. Clin Exp Dermatol. 2024, 49:286-8. 10.1093\/ced\/llad389","journal-title":"Clin Exp Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434950-targeting-the-il-36-pathway-spesolimab-as-a-therapeutic-for-acute-flares-of-pustular-psoriasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:46:28Z","timestamp":1769165188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434950-targeting-the-il-36-pathway-spesolimab-as-a-therapeutic-for-acute-flares-of-pustular-psoriasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.102134","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}